Consolidated total revenue from the sale of products in the quarter under review stood at Rs 6,589.22 crore, up 14.41%, as against Rs 5,759.28 crore in the year-ago period.
Its total expenses in the September quarter were 8.43% higher at Rs 5,260.24 crore as compared to Rs 4,851.13 crore in the corresponding period last fiscal, the company said.
Total income of Cipla in the September quarter was at Rs 6,854.47 crore, up 15.17%.
During the quarter, its revenue from pharmaceuticals was at Rs 6,452.54 crore, and from new ventures at Rs 263.77 crore.
Shares of Cipla Ltd were trading at Rs 1,179.70 on BSE on Friday, up 2.57% from the previous close.